Zhao Shengqiao,Sun Chao.Advances in the diagnosis and treatment of EBV associated lymphoproliferative disease in pediatric liver transplant recipients[J].Journal of Clinical Pediatric Surgery,2023,22(01):79-83.[doi:10.3760/cma.j.cn101785-202203015-015]
儿童肝移植术后EB病毒相关淋巴组织增生性疾病的诊治进展
- Title:
- Advances in the diagnosis and treatment of EBV associated lymphoproliferative disease in pediatric liver transplant recipients
- 摘要:
- EB病毒(Epstein-Barr virus,EBV)感染在儿童肝移植术后较为常见,而EBV相关的移植后淋巴组织增生性疾病(posttransplant lymphoproliferative disease,PTLD)是儿童肝移植术后的严重并发症,可导致受者死亡。近年来儿童肝移植术后EBV感染、病毒载量监测、EBV相关PTLD生物标志物、EBV疫苗及使用利妥昔单抗等药物治疗等方面的研究均有不同程度进展,患者预后较前也明显改善。本文就儿童肝移植术后EBV相关PTLD的诊治进展进行综述。
- Abstract:
- EBV infection is common after pediatric liver transplantation.And EBV related posttransplant lymphoproliferative disease (PTLD) is a potentially lethal complication.Recently great strides have been made in the managements of EBV infection,PTLD,viral load monitoring,detecting new biomarkers and EBV vaccination,etc.This review focused upon the latest advances in the diagnosis and treatment of EBV related PTLD after pediatric liver transplantation.
参考文献/References:
[1] Tran LT,Carullo PC,Banh D,et al.Pediatric liver transplantation:then and now[J].J Cardiothorac Vasc Anesth,2020,34(8):2028-2035.DOI:10.1053/j.jvca.2020.02.019.
[2] ?z?ay F.Lymphoproliferative disease after pediatric liver transplant[J].Exp Clin Transplant,2017,15(Suppl 2):79-81.DOI:10.6002/ect.TOND16.L22.
[3] Fishman JA.Infection in organ transplantation[J].Am J Transplant,2017,17(4):856-879.DOI:10.1111/ajt.14208.
[4] Jothimani D,Venugopal R,Vij M,et al.Post liver transplant recurrent and de novo viral infections[J].Best Pract Res Clin Gastroenterol,2020,46-47:101689.DOI:10.1016/j.bpg.2020.101689.
[5] Baker A,Frauca Remacha E,Torres Canizales J,et al.Current practices on diagnosis,prevention and treatment of post-transplant lymphoproliferative disorder in pediatric patients after solid organ transplantation:results of ern transplantchild healthcare working group survey[J].Children (Basel),2021,8(8):661.DOI:10.3390/children8080661.
[6] Dunmire SK,Hogquist KA,Balfour HH.Infectious mononucleosis[J].Curr Top Microbiol Immunol,2015,390(Pt 1):211-240.DOI:10.1007/978-3-319-22822-8_9.
[7] Qin T,Gu XQ,Jeong SS,et al.Impact of EBV infection and immune function assay for lymphoproliferative disorder in pediatric patients after liver transplantation:a single-center experience[J].Hepatobiliary Pancreat Dis Int,2020,19(1):3-11.DOI:10.1016/j.hbpd.2019.12.005.
[8] Hwang CS,Macconmara M,Desai DM.Pediatric abdominal organ transplantation[J].Surg Clin North Am,2019,99(1):73-85.DOI:10.1016/j.suc.2018.09.006.
[9] L’Huillier AG,Dipchand AI,Ng VL,et al.Posttransplant lymphoproliferative disorder in pediatric patients:characteristics of disease in ebv-seropositive recipients[J].Transplantation,2019,103(11):e369-e374.DOI:10.1097/TP.0000000000002898.
[10] Seo E,Kim J,Oh SH,et al.Epstein-Barr viral load monitoring for diagnosing post-transplant lymphoproliferative disorder in pediatric liver transplant recipients[J].Pediatr Transplant,2020,24(4):e13666.DOI:10.1111/petr.13666.
[11] Bunchorntavakul C,Reddy KR.Epstein-barr virus and cytomegalovirus infections of the liver[J].Gastroenterol Clin North Am,2020,49(2):331-346.DOI:10.1016/j.gtc.2020.01.008.
[12] 艾亮,张盛,王强,等.EB病毒相关性移植后淋巴组织增生性疾病生物标志物的相关进展[J].器官移植,2021,12(6):767-772.DOI:10.3969/j.issn.1674-7445.2021.06.019. Ai L,Zhang S,Wang Q,et al.Advances on biomarkers of EB virus-related posttransplant lymphoproliferative disease[J].Organ Transplantation,2021,12(6):767-772.DOI:10.3969/j.issn.1674-7445.2021.06.019.
[13] Huang JG,Tan M,Quak SH,et al.Risk factors and clinical outcomes of pediatric liver transplant recipients with post-transplant lymphoproliferative disease in a multi-ethnic asian cohort[J].Transpl Infect Dis,2018,20(1).DOI:10.1111/tid.12798.
[14] Bar?? Z,?z?ay F,Y?lmaz ??,et al.A single-center experience of post-transplant lymphoproliferative disorder (PTLD) cases after pediatric liver transplantation:Incidence,outcomes,and association with food allergy[J].Turk J Gastroenterol,2018,29(3):354-360.DOI:10.5152/tjg.2018.17731.
[15] Grimm KE,O’Malley DP.Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues[J].Ann Diagn Pathol,2019,38:6-10.DOI:10.1016/j.anndiagpath.2018.09.014.
[16] Tajima T,Hata K,Haga H,et al.Post-transplant lymphoproliferative disorders after liver transplantation:a retrospective cohort study including 1954 transplants[J].Liver Transpl,2021,27(8):1165-1180.DOI:10.1002/lt.26034.
[17] Song H,Guja KE,Iagaru A.(18)F-FDG PET/CT for Evaluation of Post-transplant lymphoproliferative disorder (PTLD)[J].Semin Nucl Med,2021,51(4):392-403.DOI:10.1053/j.semnuclmed.2020.12.009.
[18] Montes de Jesus FM,Glaudemans A,Tissing WJ,et al.(18)F-FDG PET/CT in the diagnostic and treatment evaluation of pediatric posttransplant lymphoproliferative disorders[J].J Nucl Med,2020,61(9):1307-1313.DOI:10.2967/jnumed.119.239624.
[19] Xu YF,Yang JG.Roles of F-18-Fluoro-2-Deoxy-Glucose PET/Computed tomography scans in the management of post-transplant lymphoproliferative disease in pediatric patient[J].PET Clin,2020,15(3):309-319.DOI:10.1016/j.cpet.2020.03.006.
[20] Guberina N,G?ckler A,Grueneisen J,et al.Assessment of Suspected Malignancy or Infection in Immunocompromised Patients After Solid Organ Transplantation by[(18)F]FDG PET/CT and[(18)F]FDG PET/MRI[J].Nucl Med Mol Imaging,2020,54(4):183-191.DOI:10.1007/s13139-020-00648-5.
[21] AbuSalah M,Gan SH,Al-Hatamleh M,et al.Recent advances in diagnostic approaches for epstein-barr virus[J].Pathogens,2020,9(3):226.DOI:10.3390/pathogens9030226.
[22] Chen HS,Ho MC,Hu RH,et al.Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation[J].J Formos Med Assoc,2019,118(9):1362-1368.DOI:10.1016/j.jfma.2018.12.007.
[23] Kanakry J,Ambinder R.The biology and clinical utility of ebv monitoring in blood[J].Curr Top Microbiol Immunol,2015,391:475-499.DOI:10.1007/978-3-319-22834-1_17.
[24] Bergallo M,Gambarino S,Pinon M,et al.EBV-encoded microRNAs profile evaluation in pediatric liver transplant recipients[J].J Clin Virol,2017,91:36-41.DOI:10.1016/j.jcv.2017.04.002.
[25] Wiesmayr S,Webber SA,Macedo C,et al.Decreased NKp46 and NKG2D and elevated PD-1 are associated with altered NK-cell function in pediatric transplant patients with PTLD[J].Eur J Immunol,2012,42(2):541-550.DOI:10.1002/eji.201141832.
[26] Huang YC,Lin SJ,Lin KM,et al.Regulation of EBV LMP1-triggered EphA4 downregulation in EBV-associated B lymphoma and its impact on patients’ survival[J].Blood,2016,128(12):1578-1589.DOI:10.1182/blood-2016-02-702530.
[27] Soriano-López DP,Alcántar-Fierros JM,Hernández-Plata JA,et al.A scheduled program of molecular screening for epstein-barr virus decreases the incidence of post-transplantation lymphoproliferative disease in pediatric liver transplantation[J].Transplant Proc,2016,48(2):654-657.DOI:10.1016/j.transproceed.2016.02.031.
[28] Kullberg-Lindh C,Saalman R,Olausson M,et al.Epstein-Barr virus DNA monitoring in serum and whole blood in pediatric liver transplant recipients who do or do not discontinue immunosuppressive therapy[J].Pediatr Transplant,2017,21(5).DOI:10.1111/petr.12875.
[29] Al Dabbagh MA,Gitman MR,Kumar D,et al.The role of antiviral prophylaxis for the prevention of epstein-barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients:a systematic review[J].Am J Transplant,2017,17(3):770-781.DOI:10.1111/ajt.14020.
[30] ?stensen AB,Sanengen T,Holter E,et al.No effect of treatment with intravenous ganciclovir on Epstein-Barr virus viremia demonstrated after pediatric liver transplantation[J].Pediatr Transplant,2017,21(6).DOI:10.1111/petr.13010.
[31] Cui X,Cao Z,Ishikawa Y,et al.Immunization with epstein-barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose ebv challenge[J].Vaccines (Basel),2021,9(3).DOI:10.3390/vaccines9030285.
[32] Cui X,Snapper CM.Epstein barr virus:development of vaccines and immune cell therapy for ebv-associated diseases[J].Front Immunol,2021,12:734471.DOI:10.3389/fimmu.2021.734471.
[33] Lindsay J,Othman J,Heldman MR,et al.Epstein-Barr virus posttransplant lymphoproliferative disorder:update on management and outcomes[J].Curr Opin Infect Dis,2021,34(6):635-645.DOI:10.1097/QCO.0000000000000787.
[34] Trappe RU,Dierickx D,Zimmermann H,et al.Response to rituximab induction is a predictive marker in b-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international,prospective,multicenter phase ii trial[J].J Clin Oncol,2017,35(5):536-543.DOI:10.1200/JCO.2016.69.3564.
[35] Allen UD,Preiksaitis JK.Post-transplant lymphoproliferative disorders,Epstein-Barr virus infection,and disease in solid organ transplantation:guidelines from the american society of transplantation infectious diseases community of practice[J].Clin Transplant,2019,33(9):e13652.DOI:10.1111/ctr.13652.
[36] Dierickx D,Habermann TM.Post-transplantation lymphoproliferative disorders in adults[J].N Engl J Med,2018,378(6):549-562.DOI:10.1056/NEJMra1702693.
[37] Serinet MO,Jacquemin E,Habes D,et al.Anti-CD20 monoclonal antibody (Rituximab) treatment for Epstein-Barr virus-associated,B-cell lymphoproliferative disease in pediatric liver transplant recipients[J].Journal of Pediatric Gastroenterology & Nutrition,2002,34(4):389.DOI:10.1001/archsurg.136.12.1386.
[38] Chiou FK,Beath SV,Patel M,et al.Hypogammaglobulinemia and bacterial infections following pediatric post-transplant lymphoproliferative disorder in the rituximab era[J].Pediatr Transplant,2019,23(6):e13519.DOI:10.1111/petr.13519.
[39] Gross TG,Bucuvalas JC,Park JR,et al.Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation[J].J Clin Oncol,2005,23(27):6481-6488.DOI:10.1200/JCO.2005.08.074.
[40] Gross TG,Orjuela MA,Perkins SL,et al.Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD):a children’s oncology group report[J].Am J Transplant,2012,12(11):3069-3075.DOI:10.1111/j.1600-6143.2012.04206.x.
[41] Taj MM,Maecker-Kolhoff B,Ling R,et al.Primary post-transplant lymphoproliferative disorder of the central nervous system:characteristics,management and outcome in 25 paediatric patients[J].Br J Haematol,2021,193(6):1178-1184.DOI:10.1111/bjh.17398.
[42] O’Reilly RJ,Prockop S,Hasan AN,et al.Virus-specific T-cell banks for ’off the shelf’ adoptive therapy of refractory infections[J].Bone Marrow Transplant,2016,51(9):1163-1172.DOI:10.1038/bmt.2016.17.
[43] Chiou FK,Beath SV,Wilkie GM,et al.Cytotoxic T-lymphocyte therapy for post-transplant lymphoproliferative disorder after solid organ transplantation in children[J].Pediatr Transplant,2018,22(2).DOI:10.1111/petr.13133.
[44] Schuster SJ,Bishop MR,Tam CS,et al.Tisagenlecleucel in adult relapsed or refractory diffuse large b-cell lymphoma[J].N Engl J Med,2019,380(1):45-56.DOI:10.1056/NEJMoa1804980.
[45] Wang T,Feng M,Luo C,et al.Successful treatment of pediatric refractory burkitt lymphoma PTLD after liver transplantation using anti-cd19 chimeric antigen receptor t-cell therapy[J].Cell Transplant,2021,30:963689721996649.DOI:10.1177/0963689721996649.
[46] Nakid-Cordero C,Baron M,Guihot A,et al.Natural killer cells in post-transplant lymphoproliferative disorders[J].Cancers (Basel),2021,13(8).DOI:10.3390/cancers13081836.
[47] Schiefer AI,Salzer E,Füreder A,et al.PD-L1 and PD1 expression in post-transplantation lymphoproliferative disease (PTLD) of childhood and adolescence:An inter- and intra-individual descriptive study covering the whole spectrum of PTLD categories[J].Cancer Med,2019,8(10):4656-4668.DOI:10.1002/cam4.2394.
[48] Bollard CM,Cohen JI.How I treat T-cell chronic active Epstein-Barr virus disease[J].Blood,2018,131(26):2899-2905.DOI:10.1182/blood-2018-03-785931.
相似文献/References:
[1]杨振宇,陈福真,李滨,等.小儿亲体部分肝移植治疗肝母细胞瘤(附1例报告)[J].临床小儿外科杂志,2007,6(02):12.
[2]唐艳,刘洋,王紫娟,等. 个体化干预模式在儿童肝移植受者术后随访中的应用[J].临床小儿外科杂志,2016,15(01):41.
[3]余晨,詹江华,高伟,等.胆道闭锁Ｋａｓａｉ术后肝移植患儿不同自体肝生存的临床与病理分析[J].临床小儿外科杂志,2017,16(06):552.
[4]彭宇明,司中州,袁妙贤,等.儿童肝移植20例诊治分析[J].临床小儿外科杂志,2019,18(08):681.[doi:10.3969/j.issn.1671-6353.2019.08.013]
Peng Yuming,Si Zhongzhou,Yuan Miaoxian,et al.Diagnoses and treatments of hepatic transplantation in 20 children[J].Journal of Clinical Pediatric Surgery,2019,18(01):681.[doi:10.3969/j.issn.1671-6353.2019.08.013]
[5]王焕民.开展新技术 提高儿童肝胆肿瘤手术治疗水平[J].临床小儿外科杂志,2020,19(05):377.[doi:10.3969/j.issn.1671-6353.2020.05.001]
Wang Huanmin.Adopting new technology to optimize the surgical treatment of hepatobiliary cancer in children[J].Journal of Clinical Pediatric Surgery,2020,19(01):377.[doi:10.3969/j.issn.1671-6353.2020.05.001]
[6]董岿然.联合肝脏离断和门静脉结扎二步肝切除术在儿童肝肿瘤治疗中的应用[J].临床小儿外科杂志,2020,19(05):382.[doi:10.3969/j.issn.1671-6353.2020.05.002]
Dong Kuiran.Application of associated liver partition and portal vein ligation for staged hepatectomy in the treatment of liver tumors in children[J].Journal of Clinical Pediatric Surgery,2020,19(01):382.[doi:10.3969/j.issn.1671-6353.2020.05.002]
[7]沈秋龙,陈亚军,彭春辉,等.肝脏硬度测量值预测胆道闭锁术后五年自体肝生存的价值研究[J].临床小儿外科杂志,2020,19(06):486.[doi:10.3969/j.issn.1671-6353.2020.06.005]
Shen Qiulong,Chen Yajun,Peng Chunhui,et al.Predicting five-year native liver survival after Kasai procedure of biliary atresia by liver stiffness measurement[J].Journal of Clinical Pediatric Surgery,2020,19(01):486.[doi:10.3969/j.issn.1671-6353.2020.06.005]
[8]隆琦,钭金法,陈菲,等.胆道闭锁Kasai术后自体肝生存良好患儿的营养状况调查[J].临床小儿外科杂志,2020,19(06):491.[doi:10.3969/j.issn.1671-6353.2020.06.006]
Long Qi,Tou Jinfa,Chen Fei,et al.Nutritional status of children with biliary atresia surviving well after Kasai surgery[J].Journal of Clinical Pediatric Surgery,2020,19(01):491.[doi:10.3969/j.issn.1671-6353.2020.06.006]
[9]刘金桥,陈文娟,尹强,等.肝动脉阻力指数对儿童肝移植术后胆道吻合口并发症的预测价值[J].临床小儿外科杂志,2020,19(11):1038.[doi:10.3969/j.issn.1671-6353.2020.11.015]
Liu Jinqiao,Chen Wenjuan,Yin Qiang,et al.Predictive value of hepatic artery resistance index for biliary anastomotic complications after liver transplantation in children[J].Journal of Clinical Pediatric Surgery,2020,19(01):1038.[doi:10.3969/j.issn.1671-6353.2020.11.015]
[10]詹江华,陈亚军.Kasai手术与肝移植治疗胆道闭锁的利弊思考[J].临床小儿外科杂志,2021,20(02):101.[doi:10.12260/lcxewkzz.2021.02.001]
Zhan Jianghua,Chen Yajun.Advantages and disadvantages of Kasai operation and liver transplantation for biliary atresia[J].Journal of Clinical Pediatric Surgery,2021,20(01):101.[doi:10.12260/lcxewkzz.2021.02.001]
备注/Memo
收稿日期:2022-03-05。
基金项目:天津市医学重点学科(专科)建设项目(TJWJ2022XK017)
通讯作者:孙超,Email:sunchaodoc@163.com